News

Eli Lilly and partner Boehringer Ingelheim say that regulators in Europe have accepted for review their biosimilar of Sanofi’s blockbuster diabetes treatment Lantus.

GlaxoSmithKline is investigating fresh allegations that staff in China were involved in paying backhanders to doctors to sell Botox in China, according to the Wall Street Journal.

Hikma Pharmaceuticals says “all of our businesses have continued to perform well” and now expects revenues to rise 17% in 2013, up from a previous forecast of a 13% increase, boosted by strong sales of its generic antibiotic doxycycline.

Novartis has entered into a development and licensing agreement with Biological E of India for two vaccines to protect against typhoid and paratyphoid fevers.

Novartis’ secukinumab has outperformed Amgen’s multi-billion-dollar drug Enbrel in a late-stage clinical trial in patients with psoriasis.

The oil-rich and rapidly-growing nation of Azerbaijan is presenting itself as a very attractive ground for global healthcare investors, and the nation’s pharmaceutical market is particularly promising, according to new research.

Having recently decided not to continue development of olokizumab despite positive mid-stage results, UCB has decided to out-license the rheumatoid arthritis drug to Russia’s R-Pharm.

The European Commission has granted Novartis a fourth approval for its eye drug Lucentis, this time to treat patients with visual impairment due to choroidal neovascularisation secondary to pathologic myopia.

Regulators in the USA have given the green light to Orexo of Sweden’s Zubsolv as a treatment for opioid addiction.

Days after beginning an investigation into price-fixing of infant milk by foreign companies, China has turned its attention to the pharmaceutical industry, both domestic and international.

Canada’s current “patchwork” system of prescription drug coverage is pushing up costs, creates massive confusion and results in significant financial hardship for some Canadians, insurance leaders have warned.

Chilean branded generics major CFR Pharmaceuticals (Corporacion Farmaceutica Recalcine) is making a cash and shares offer to buy South African group Adcock Ingram in a deal valued at 12.90 billion rand, around $1.30 billion.

The continuing under-representation of minority populations in clinical studies is depriving some of the most vulnerable people in the US of better tailored treatment options, the founder of a trial search website warns.

CureLaucher, a US-based matching service for clinical trials, is extending its social-media reach through an exclusive partnership with the Treatment Diaries network.

A project supported by a 6 million euro grant from the European Union to develop biomarker-guided actively personalised vaccines to treat glioblastoma, the aggressive form of brain cancer with poor prognosis, has been launched.